Publication | Open Access

Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial

Urothelial CarcinomasMedicineClinical TrialsPathologyImmune Checkpoint InhibitorGastro-oesophageal CancerPharmacotherapyCancer TreatmentOncologyRadiation OncologyLung CancerHealth Sciences